Doctor Christopher Blaum
University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Evaluating risk-based allocation strategies for PCSK9 inhibitors: results from a simulation study in a contemporary ASCVD cohort
Event: ESC Congress 2023
Topic: Drug therapy
Session: Risk factors and prevention: lipids (2)
Inflammatory risk: predictions
Event: ESC Preventive Cardiology 2023
Topic: Biomarkers
Session: Inflammation-driven cardiovascular risk
Target populations and treatment cost for bempedoic acid and PCSK9 inhibitors: a simulation study in a contemporary CAD cohort
Event: ESC Congress 2021 - The Digital Experience
Topic: Lipid-Lowering Agents
Session: Highlights from the Young on cutting edge therapy for lowering lipids
Risk scores for risk stratification in chronic coronary syndrome and their improvement by Gensini and SYNTAX scores
Event: ESC Congress 2021 - The Digital Experience
Topic: Epidemiology, Prognosis, Outcome
Session: Coronary Artery Disease (Chronic)/Chronic Coronary Syndromes ePosters
The impact of the revised ESC Dyslipidaemia Guidelines on lipid-lowering therapy: simulating the need for PCSK9 inhibition in a contemporary ASCVD cohort
Event: ESC Congress 2020
Topic: Drug therapy
Session: Risk Factors and Prevention ePosters
The impact of modifiable life style risk factors on inflammation in patients with coronary artery disease: modelling a target population for anti-inflammatory treatment
Event: ESC Congress 2019
Topic: Lifestyle Modification
Session: CAD - Lifestyle modification and non-pharmacological treatment
ESC 365 is supported by
